Johnson and Johnson Ortho-ATI® shoulder tendon results

Well here we are end of September with the start of the 4th Quarter rolling around on Friday.

I would be amazed if management didn't get these results out before the AGM scheduled for 27th October at 9am AWST so under a month to get, this is in my view the biggest moment in OCC's history due to the fact the study is with the biggest Pharma in the world.

Like a long run the final meters are the hardest to take mentally but OCC post these could be anything price wise, so much potential from around 50 cents.

Ortho-ATI® shoulder tendon study update• The last patient treated in the randomised clinical study comparing Orthocell’s tendon regeneration therapy (Ortho-ATI®) to corticosteroids has completed their 12-month follow up;

• Final data collection and validation is in progress, results expected in Q4, 2021
• Ortho-ATI® shoulder tendon study is the first high-quality randomised controlled study completed for this indication;
• There are currently no proven long-term non-surgical solutions to repair chronic shoulder tendon injuries;
• Ortho-ATI® is well positioned to become the first FDA approved injectable cell therapy in orthopaedics for the treatment of chronic tendon injuries;